Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells.

Beug ST, Korneluk RG, LaCasse EC.

Mol Cell Oncol. 2019 May 8;6(4):1607456. doi: 10.1080/23723556.2019.1607456. eCollection 2019.

PMID:
31211235
2.

Targeted ablation of the cellular inhibitor of apoptosis 1 (cIAP1) attenuates denervation-induced skeletal muscle atrophy.

Lala-Tabbert N, Lejmi-Mrad R, Timusk K, Fukano M, Holbrook J, St-Jean M, LaCasse EC, Korneluk RG.

Skelet Muscle. 2019 May 24;9(1):13. doi: 10.1186/s13395-019-0201-6.

3.

The transcription factor SP3 drives TNF-α expression in response to Smac mimetics.

Beug ST, Cheung HH, Sanda T, St-Jean M, Beauregard CE, Mamady H, Baird SD, LaCasse EC, Korneluk RG.

Sci Signal. 2019 Jan 29;12(566). pii: eaat9563. doi: 10.1126/scisignal.aat9563.

PMID:
30696705
4.

Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression.

Beug ST, Pichette SJ, St-Jean M, Holbrook J, Walker DE, LaCasse EC, Korneluk RG.

Mol Ther Oncolytics. 2018 Jun 21;10:28-39. doi: 10.1016/j.omto.2018.06.002. eCollection 2018 Sep 28.

5.

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2018 Jul 18;9:16231. doi: 10.1038/ncomms16231.

6.

Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization.

Morón-Calvente V, Romero-Pinedo S, Toribio-Castelló S, Plaza-Díaz J, Abadía-Molina AC, Rojas-Barros DI, Beug ST, LaCasse EC, MacKenzie A, Korneluk R, Abadía-Molina F.

PLoS One. 2018 Mar 8;13(3):e0193643. doi: 10.1371/journal.pone.0193643. eCollection 2018.

7.

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2017 Feb 15;8. doi: 10.1038/ncomms14278. Erratum in: Nat Commun. 2018 Jul 18;9:16231.

8.

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.

Dobson CC, Naing T, Beug ST, Faye MD, Chabot J, St-Jean M, Walker DE, LaCasse EC, Stojdl DF, Korneluk RG, Holcik M.

Oncotarget. 2017 Jan 10;8(2):3495-3508. doi: 10.18632/oncotarget.13849.

9.

How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease.

Nielsen OH, LaCasse EC.

Genet Med. 2017 Feb;19(2):133-143. doi: 10.1038/gim.2016.82. Epub 2016 Jul 14. Review.

PMID:
27416006
10.

Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists.

Beug ST, Conrad DP, Alain T, Korneluk RG, Lacasse EC.

Int J Dev Biol. 2015;59(1-3):141-7. doi: 10.1387/ijdb.150084el. Review.

11.

Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists.

Beug ST, Conrad DP, Alain T, Korneluk RG, Lacasse EC.

Int J Dev Biol. 2015 May 21. [Epub ahead of print]

PMID:
26009240
12.

The inhibitors of apoptosis (IAPs): Over 20 years of research into life and death.

LaCasse EC, Beug ST, Korneluk RG.

Semin Cell Dev Biol. 2015 Mar;39:70-1. doi: 10.1016/j.semcdb.2015.04.002. No abstract available.

PMID:
25910657
13.

Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation.

Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH.

Trends Mol Med. 2014 Nov;20(11):652-65. doi: 10.1016/j.molmed.2014.09.006. Epub 2014 Oct 1. Review.

PMID:
25282548
14.

Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells.

Beug ST, LaCasse EC, Korneluk RG.

Oncoimmunology. 2014 Apr 29;3:e28541. eCollection 2014.

15.

Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis.

Enwere EK, Lacasse EC, Adam NJ, Korneluk RG.

Front Immunol. 2014 Feb 5;5:34. doi: 10.3389/fimmu.2014.00034. eCollection 2014. Review.

16.

Smac mimetics and innate immune stimuli synergize to promote tumor death.

Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, Dastidar H, Mahoney DJ, Ilkow C, Le Boeuf F, Bell JC, Korneluk RG.

Nat Biotechnol. 2014 Feb;32(2):182-90. doi: 10.1038/nbt.2806. Epub 2014 Jan 26.

17.

Modulation of immune signalling by inhibitors of apoptosis.

Beug ST, Cheung HH, LaCasse EC, Korneluk RG.

Trends Immunol. 2012 Nov;33(11):535-45. doi: 10.1016/j.it.2012.06.004. Epub 2012 Jul 24. Review.

PMID:
22836014
18.

Pulling the plug on a cancer cell by eliminating XIAP with AEG35156.

LaCasse EC.

Cancer Lett. 2013 May 28;332(2):215-24. doi: 10.1016/j.canlet.2012.06.015. Epub 2012 Jul 7. Review.

PMID:
22776562
19.

Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound.

Cheung HH, Mahoney DJ, Lacasse EC, Korneluk RG.

Cancer Res. 2009 Oct 1;69(19):7729-38. doi: 10.1158/0008-5472.CAN-09-1794. Epub 2009 Sep 22.

20.

IAP-targeted therapies for cancer.

LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG.

Oncogene. 2008 Oct 20;27(48):6252-75. doi: 10.1038/onc.2008.302. Review.

PMID:
18931692
21.

Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation.

Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG.

Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11778-83. doi: 10.1073/pnas.0711122105. Epub 2008 Aug 12.

22.

Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo.

Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC.

Int J Cancer. 2008 Mar 15;122(6):1430-4.

23.

The role of XAF1 in cancer.

Plenchette S, Cheung HH, Fong WG, LaCasse EC, Korneluk RG.

Curr Opin Investig Drugs. 2007 Jun;8(6):469-76. Review.

PMID:
17621877
24.

The inhibitors of apoptosis (IAPs) as cancer targets.

Hunter AM, LaCasse EC, Korneluk RG.

Apoptosis. 2007 Sep;12(9):1543-68. Review.

PMID:
17573556
25.

Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.

Micali OC, Cheung HH, Plenchette S, Hurley SL, Liston P, LaCasse EC, Korneluk RG.

BMC Cancer. 2007 Mar 21;7:52.

26.

XIAP protection of photoreceptors in animal models of retinitis pigmentosa.

Leonard KC, Petrin D, Coupland SG, Baker AN, Leonard BC, LaCasse EC, Hauswirth WW, Korneluk RG, Tsilfidis C.

PLoS One. 2007 Mar 21;2(3):e314.

27.

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.

LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP.

Clin Cancer Res. 2006 Sep 1;12(17):5231-41.

28.

Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells.

Liu Z, Li H, Wu X, Yoo BH, Yan SR, Stadnyk AW, Sasazuki T, Shirasawa S, LaCasse EC, Korneluk RG, Rosen KV.

Oncogene. 2006 Dec 14;25(59):7680-90. Epub 2006 Jun 26.

PMID:
16799641
29.

X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment.

Cheung HH, LaCasse EC, Korneluk RG.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3238-42. Review. No abstract available.

30.

Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640.

Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J.

Ann N Y Acad Sci. 2005 Nov;1058:215-34. Review.

PMID:
16394139
32.

ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation.

Liu Z, Li H, Derouet M, Filmus J, LaCasse EC, Korneluk RG, Kerbel RS, Rosen KV.

J Biol Chem. 2005 Nov 11;280(45):37383-92. Epub 2005 Aug 22.

33.

Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics.

McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC.

Oncogene. 2004 Oct 21;23(49):8105-17.

PMID:
15378029
34.

Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.

Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC.

Clin Cancer Res. 2003 Jul;9(7):2826-36.

35.

Evidence for apoptosis in the fetal Down syndrome brain.

Seidl R, Bidmon B, Bajo M, Yoo PC, Cairns N, LaCasse EC, Lubec G.

J Child Neurol. 2001 Jun;16(6):438-42.

PMID:
11417611
36.

Neuronal apoptosis inhibitory protein (NAIP)-like immunoreactivity in brains of adult patients with Down syndrome.

Seidl R, Bajo M, Böhm K, LaCasse EC, MacKenzie AE, Cairns N, Lubec G.

J Neural Transm Suppl. 1999;57:283-91.

PMID:
10666683
37.

Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.

LaCasse EC, Bray MR, Patterson B, Lim WM, Perampalam S, Radvanyi LG, Keating A, Stewart AK, Buckstein R, Sandhu JS, Miller N, Banerjee D, Singh D, Belch AR, Pilarski LM, Gariépy J.

Blood. 1999 Oct 15;94(8):2901-10.

38.

The inhibitors of apoptosis (IAPs) and their emerging role in cancer.

LaCasse EC, Baird S, Korneluk RG, MacKenzie AE.

Oncogene. 1998 Dec 24;17(25):3247-59. Review.

39.

Penetration and intracellular routing of nucleus-directed peptide-based shuttles (loligomers) in eukaryotic cells.

Singh D, Kiarash R, Kawamura K, LaCasse EC, Gariépy J.

Biochemistry. 1998 Apr 28;37(17):5798-809.

PMID:
9558313
40.

Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice.

LaCasse EC, Saleh MT, Patterson B, Minden MD, Gariépy J.

Blood. 1996 Sep 1;88(5):1561-7.

41.

Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins.

LaCasse EC, Lefebvre YA.

Nucleic Acids Res. 1995 May 25;23(10):1647-56. Review. No abstract available.

42.

Identification of binding proteins for nuclear localization signals of the glucocorticoid and thyroid hormone receptors.

LaCasse EC, Lochnan HA, Walker P, Lefebvre YA.

Endocrinology. 1993 Dec;133(6):2760. No abstract available.

PMID:
8243301
43.

Identification of binding proteins for nuclear localization signals of the glucocorticoid and thyroid hormone receptors.

LaCasse EC, Lochnan HA, Walker P, Lefebvre YA.

Endocrinology. 1993 Mar;132(3):1017-25. Erratum in: Endocrinology. 1993 Dec;133(6):2760.

PMID:
8440170
44.
45.

Microsomal dexamethasone binding sites identified by affinity labelling.

LaCasse EC, Howell GM, Lefebvre YA.

J Steroid Biochem. 1990 Jan;35(1):47-54.

PMID:
2308330

Supplemental Content

Loading ...
Support Center